

**JUSTICE DATA AND INVESTIGATIVE SERVICES BUREAU  
CURES PROGRAM**Telephone: (916) 210-3187  
E-Mail Address: CURES@doj.ca.gov

December 3, 2025

TO: ALL CURES DATA SUBMITTERS

RE: AB 82 – UPDATE ON REPORTING OF TESTOSTERONE AND MIFEPRISTONE

[Assembly Bill \(AB\) 82](#) (Ward, Chapter 679, Statutes of 2025), signed into law on October 13, 2025, directly impacts dispensers who report specified medications to the Controlled Substance Utilization Review and Evaluation System (CURES), the statewide prescription drug monitoring program database maintained by the California Department of Justice (DOJ).

Existing law requires pharmacists and other dispensers to report information relating to prescriptions of Schedule II, III, IV, and V controlled substances to CURES.<sup>1</sup>

Specifically, AB 82 requires:

- **Effective January 1, 2026**  
The dispensing of **testosterone** or **mifepristone** **shall not** be reported to DOJ, CURES, or its contracted prescription data processing vendor.<sup>2</sup>
- **On or before January 1, 2027**  
DOJ shall remove existing records for testosterone or mifepristone which are in CURES prior to January 1, 2026.<sup>3</sup>

To reiterate, dispensers ***must not*** report any dispensations of testosterone or mifepristone to PMP Clearinghouse effective January 1, 2026. If any records for testosterone or mifepristone are inadvertently reported to PMP Clearinghouse, DOJ will make every effort to identify those records and prevent them from being loaded into the CURES database. However, dispensers are ultimately responsible for adhering to the requirement to not report testosterone and mifepristone.

<sup>1</sup> Health & Safety Code (HSC) sections 11165(d) & 11190(c). Reporting of Schedule V controlled substances is limited to HSC section 11165(d).

<sup>2</sup> HSC section 11165(k)(1).

<sup>3</sup> HSC section 11165(k)(2).

December 3, 2025

Page 2

If you have additional questions regarding AB 82, please contact your licensing board with the Department of Consumer Affairs. For CURES-related questions, you may contact the CURES Program at [cures@doj.ca.gov](mailto:cures@doj.ca.gov) or (916) 210-3187.